Talha Badar: Clinical outcome of AYA with Ph+ve ALL
Talha Badar shared on X: .
“Clinical outcome of adolescents and young adults (AYA) with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ve ALL).
Additional cytogenetic abnormalities are similar in both age groups.
Comparable proportions of patients received intensive chemotherapy (IC) plus tyrosine kinase inhibitors (TKI) and allo-HCT in AYA and non-AYA.”
Source: Talha Badar/X
Dr. Talha Badar, MD, is a specialist in Hematology Oncology based in Mayo Clinic, Jacksonville, Florida. His primary areas of expertise include Leukemia, particularly Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Lymphoblastic Leukemia (ALL), and Bone Marrow Transplantation. Over his career, he has actively contributed to clinical research and clinical trials.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023